RU2002125944A - Производные хинолина в качестве альфа-2-антагонистов - Google Patents

Производные хинолина в качестве альфа-2-антагонистов

Info

Publication number: RU2002125944A
Authority: RU; Russia
Prior art keywords: alkyl; halogen; phenyl; compound; alkoxy
Prior art date: 2000-03-01

Application number

RU2002125944/04A

Other languages

English (en)

Russian (ru)

Inventor

Зигфрид ВУРСТЕР (FI)

Зигфрид ВУРСТЕР

Миа ЭНГСТРЕМ (FI)

Миа ЭНГСТРЕМ

Юха-Матти САВОЛА (FI)

Юха-Матти САВОЛА

Ииса ХЕГЛУНД (FI)

Ииса Хеглунд

Юкка САЛЛИНЕН (FI)

Юкка Саллинен

Антти ХААПАЛИННА (FI)

Антти Хаапалинна

Андрей Юрьевич ТАУБЕР (FI)

Андрей Юрьевич ТАУБЕР

Анна-Марь ХОФФРЕН (FI)

Анна-Марья ХОФФРЕН

Харри САЛО (FI)

Харри Сало

Original Assignee

Орион Корпорейшн (Fi)

Орион Корпорейшн

Ой Ювантиа Фарма Лтд. (Fi)

Ой Ювантиа Фарма Лтд.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-01

Filing date

2001-02-28

Publication date

2004-02-27

2001-02-28 Application filed by Орион Корпорейшн (Fi), Орион Корпорейшн, Ой Ювантиа Фарма Лтд. (Fi), Ой Ювантиа Фарма Лтд. filed Critical Орион Корпорейшн (Fi)

2004-02-27 Publication of RU2002125944A publication Critical patent/RU2002125944A/ru

Links

SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 1
239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 title 1
229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 45
150000001875 compounds Chemical class 0.000 claims 40
229910052736 halogen Inorganic materials 0.000 claims 37
-1 1-imidazolyl Chemical group 0.000 claims 27
150000002367 halogens Chemical class 0.000 claims 26
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 25
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 23
125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 21
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 14
125000001424 substituent group Chemical group 0.000 claims 11
150000002148 esters Chemical class 0.000 claims 10
150000003839 salts Chemical class 0.000 claims 10
125000004432 carbon atom Chemical group C* 0.000 claims 9
125000004433 nitrogen atom Chemical group N* 0.000 claims 7
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 6
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
150000001412 amines Chemical class 0.000 claims 5
125000004429 atom Chemical group 0.000 claims 5
125000002837 carbocyclic group Chemical group 0.000 claims 5
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims 4
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
125000005115 alkyl carbamoyl group Chemical group 0.000 claims 4
125000000623 heterocyclic group Chemical group 0.000 claims 4
125000001624 naphthyl group Chemical group 0.000 claims 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
239000003814 drug Substances 0.000 claims 3
238000004519 manufacturing process Methods 0.000 claims 3
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
125000005842 heteroatom Chemical group 0.000 claims 2
UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical group C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 claims 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
GZPDMTWJWCKXNJ-UHFFFAOYSA-N 2-[4-[4-(1,2,3,4-tetrahydroacridin-9-ylamino)phenyl]piperazin-1-yl]ethanol Chemical compound C1CN(CCO)CCN1C(C=C1)=CC=C1NC1=C(CCCC2)C2=NC2=CC=CC=C12 GZPDMTWJWCKXNJ-UHFFFAOYSA-N 0.000 claims 1
VBDVCLHMPVSOQZ-UHFFFAOYSA-N 2-[4-[4-(acridin-9-ylamino)phenyl]piperazin-1-yl]ethanol Chemical compound C1CN(CCO)CCN1C(C=C1)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 VBDVCLHMPVSOQZ-UHFFFAOYSA-N 0.000 claims 1
YEGLCEJPSSYEQE-UHFFFAOYSA-N 3-ethyl-2-methyl-n-[4-(4-methylpiperazin-1-yl)phenyl]quinolin-4-amine Chemical compound CCC1=C(C)N=C2C=CC=CC2=C1NC(C=C1)=CC=C1N1CCN(C)CC1 YEGLCEJPSSYEQE-UHFFFAOYSA-N 0.000 claims 1
BXVCYRBPPBQKEN-UHFFFAOYSA-N 4-[4-(4-methylpiperazin-1-yl)anilino]quinoline-3-carbonitrile Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=C(C#N)C=NC2=CC=CC=C12 BXVCYRBPPBQKEN-UHFFFAOYSA-N 0.000 claims 1
DUYKGBPLYMVLEY-UHFFFAOYSA-N 4-[4-[(6-chloro-2-methoxyacridin-9-yl)amino]phenyl]-n,n-diethylpiperazine-1-carboxamide Chemical compound C1CN(C(=O)N(CC)CC)CCN1C(C=C1)=CC=C1NC1=C(C=CC(Cl)=C2)C2=NC2=CC=C(OC)C=C12 DUYKGBPLYMVLEY-UHFFFAOYSA-N 0.000 claims 1
XMXAKWQIZRUKOE-UHFFFAOYSA-N 4-[4-[(7-chloro-2-methylquinolin-4-yl)amino]phenyl]-n,n-diethylpiperazine-1-carboxamide Chemical compound C1CN(C(=O)N(CC)CC)CCN1C(C=C1)=CC=C1NC1=CC(C)=NC2=CC(Cl)=CC=C12 XMXAKWQIZRUKOE-UHFFFAOYSA-N 0.000 claims 1
125000004559 acridin-9-yl group Chemical group C1=CC=CC2=NC3=CC=CC=C3C(=C12)* 0.000 claims 1
239000004480 active ingredient Substances 0.000 claims 1
239000000674 adrenergic antagonist Substances 0.000 claims 1
125000003545 alkoxy group Chemical group 0.000 claims 1
239000005557 antagonist Substances 0.000 claims 1
150000001555 benzenes Chemical group 0.000 claims 1
229910052799 carbon Inorganic materials 0.000 claims 1
210000003169 central nervous system Anatomy 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 1
KJQWJHXJHKKTTD-UHFFFAOYSA-N n-[4-(4-benzylpiperazin-1-yl)phenyl]acridin-9-amine Chemical compound C1CN(C=2C=CC(NC=3C4=CC=CC=C4N=C4C=CC=CC4=3)=CC=2)CCN1CC1=CC=CC=C1 KJQWJHXJHKKTTD-UHFFFAOYSA-N 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Endocrinology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)

RU2002125944/04A 2000-03-01 2001-02-28 Производные хинолина в качестве альфа-2-антагонистов RU2002125944A (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FI20000480		2000-03-01
FI20000480A FI20000480A0 (fi)	2000-03-01	2000-03-01	Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina

Publications (1)

Publication Number	Publication Date
RU2002125944A true RU2002125944A (ru)	2004-02-27

Family

ID=8557801

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2002125944/04A RU2002125944A (ru)	2000-03-01	2001-02-28	Производные хинолина в качестве альфа-2-антагонистов

Country Status (21)

Country	Link
EP (1)	EP1263733A2 (es)
JP (1)	JP2003525274A (es)
KR (1)	KR20020089372A (es)
CN (1)	CN1468224A (es)
AR (1)	AR034249A1 (es)
AU (1)	AU2001239331A1 (es)
BR (1)	BR0108816A (es)
CA (1)	CA2400657A1 (es)
CZ (1)	CZ20022880A3 (es)
EE (1)	EE200200490A (es)
FI (1)	FI20000480A0 (es)
HU (1)	HUP0204458A3 (es)
IL (1)	IL151093A0 (es)
MX (1)	MXPA02008402A (es)
NO (1)	NO20024159D0 (es)
PE (1)	PE20011084A1 (es)
PL (1)	PL357874A1 (es)
RU (1)	RU2002125944A (es)
SK (1)	SK12332002A3 (es)
WO (1)	WO2001064645A2 (es)
ZA (1)	ZA200206956B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003066604A2 (en) *	2002-02-05	2003-08-14	Novo Nordisk A/S	Novel aryl- and heteroarylpiperazines
RU2361869C2 (ru) *	2002-02-05	2009-07-20	ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи	Новые арил- и гетероарилпиперазины
DE60316672T2 (de)	2002-04-03	2008-07-17	Orion Corp.	Polycyclische verbindungen als potente alpha2-adrenoceptor antagonisten
AU2003219199A1 (en) *	2002-04-03	2003-10-13	Orion Corporation	Use of an alfa2-adrenoreceptor antagonist for cns-related diseases
CN1304374C (zh) *	2002-04-30	2007-03-14	永进药品工业株式会社	可用做caspase－3抑制剂的喹啉衍生物及其制备方法和药用组合物
WO2004067513A1 (en) *	2003-01-27	2004-08-12	Oy Juvantia Pharma Ltd	Antagonists for alpha-2 adrenoceptors
KR101286569B1 (ko)	2005-07-04	2013-07-23	하이 포인트 파마슈티칼스, 엘엘씨	신규 약제
US8183239B2 (en)	2005-10-31	2012-05-22	Janssen Pharmaceutica Nv	Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor
EP1968961A2 (en)	2005-12-21	2008-09-17	Decode Genetics EHF	Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
EP2029553A1 (en) *	2006-05-22	2009-03-04	Janssen Pharmaceutica, N.V.	Substituted pyrazinone derivatives for use as a medicine
JP2009537596A (ja)	2006-05-23	2009-10-29	ハイポイントファーマシューティカルズ，リミティドライアビリティカンパニー	６−（４−シクロプロピルピペリジン−１−イル）−２’−メチル−［３，４’］−ビピリジン及びその医薬としての使用
CN102295606A (zh)	2006-05-29	2011-12-28	高点制药有限责任公司	合成3-（1，3-苯并间二氧杂环戊烯-5-基）-6-（4-环丙基哌嗪-1-基）-哒嗪的方法及其适用的中间体
EP2014656A3 (en)	2007-06-11	2011-08-24	High Point Pharmaceuticals, LLC	New heteocyclic h3 antagonists
TWI457122B (zh)	2007-07-20	2014-10-21	Orion Corp	作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
TW201026691A (en)	2008-10-07	2010-07-16	Schering Corp	Biaryl spiroaminooxazoline analogues as alpha2C adrenergic receptor modulators
TW201024282A (en)	2008-11-20	2010-07-01	Orion Corp	New pharmaceutical compounds
AU2010329847A1 (en) *	2009-12-11	2012-07-26	Genecode As	Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
CN103524413B (zh) *	2012-07-04	2016-04-20	江苏先声药物研究有限公司	氢化吖啶衍生物及其应用
JOP20200052A1 (ar) *	2013-12-19	2017-06-16	Bayer Pharma AG	بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
CA2944462A1 (en)	2014-03-31	2015-10-08	MiRx Pharmaceuticals, LLC	Novel hdmx inhibitors and their use for cancer treatment
WO2016135139A1 (en)	2015-02-23	2016-09-01	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135140A1 (en)	2015-02-23	2016-09-01	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135137A1 (en)	2015-02-23	2016-09-01	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135138A1 (en)	2015-02-23	2016-09-01	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
CN107337641B (zh) *	2017-07-01	2020-04-28	广东医科大学	一种4-柔性胺基-2-芳乙烯基喹啉类衍生物及其制备方法和应用
AU2022341967A1 (en) *	2021-09-07	2024-05-16	Gismo Therapeutics, Inc.	Compounds and pharmaceutical compositions comprising inhibitors of amyloid peptide interactions with glycosaminoglycans, methods of treatment, and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9510757D0 (en) *	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds

2000
- 2000-03-01 FI FI20000480A patent/FI20000480A0/fi unknown
2001
- 2001-02-28 JP JP2001563488A patent/JP2003525274A/ja active Pending
- 2001-02-28 SK SK1233-2002A patent/SK12332002A3/sk unknown
- 2001-02-28 BR BR0108816-5A patent/BR0108816A/pt not_active Application Discontinuation
- 2001-02-28 PL PL01357874A patent/PL357874A1/xx not_active Application Discontinuation
- 2001-02-28 EE EEP200200490A patent/EE200200490A/xx unknown
- 2001-02-28 CN CNA018059236A patent/CN1468224A/zh active Pending
- 2001-02-28 RU RU2002125944/04A patent/RU2002125944A/ru not_active Application Discontinuation
- 2001-02-28 MX MXPA02008402A patent/MXPA02008402A/es unknown
- 2001-02-28 AU AU2001239331A patent/AU2001239331A1/en not_active Abandoned
- 2001-02-28 CA CA002400657A patent/CA2400657A1/en not_active Abandoned
- 2001-02-28 EP EP01913918A patent/EP1263733A2/en not_active Withdrawn
- 2001-02-28 KR KR1020027011453A patent/KR20020089372A/ko not_active Withdrawn
- 2001-02-28 HU HU0204458A patent/HUP0204458A3/hu unknown
- 2001-02-28 CZ CZ20022880A patent/CZ20022880A3/cs unknown
- 2001-02-28 WO PCT/FI2001/000203 patent/WO2001064645A2/en not_active Ceased
- 2001-02-28 IL IL15109301A patent/IL151093A0/xx unknown
- 2001-03-01 AR ARP010100993A patent/AR034249A1/es unknown
- 2001-03-01 PE PE2001000208A patent/PE20011084A1/es not_active Application Discontinuation
2002
- 2002-08-29 ZA ZA200206956A patent/ZA200206956B/en unknown
- 2002-08-30 NO NO20024159A patent/NO20024159D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
BR0108816A (pt)	2002-12-10
HUP0204458A3 (en)	2004-07-28
CZ20022880A3 (cs)	2003-06-18
JP2003525274A (ja)	2003-08-26
PL357874A1 (en)	2004-07-26
SK12332002A3 (sk)	2003-07-01
PE20011084A1 (es)	2001-10-25
WO2001064645A2 (en)	2001-09-07
CN1468224A (zh)	2004-01-14
HUP0204458A2 (hu)	2003-04-28
CA2400657A1 (en)	2001-09-07
MXPA02008402A (es)	2003-10-14
AU2001239331A1 (en)	2001-09-12
IL151093A0 (en)	2003-04-10
AR034249A1 (es)	2004-02-18
NO20024159L (no)	2002-08-30
EE200200490A (et)	2003-12-15
KR20020089372A (ko)	2002-11-29
NO20024159D0 (no)	2002-08-30
ZA200206956B (en)	2003-12-01
FI20000480A0 (fi)	2000-03-01
WO2001064645A3 (en)	2001-12-27
EP1263733A2 (en)	2002-12-11

Publication	Publication Date	Title
RU2002125944A (ru)	2004-02-27	Производные хинолина в качестве альфа-2-антагонистов
RU2309951C2 (ru)	2007-11-10	Производные никотинамида, способы их получения, фармацевтическая композиция на их основе и применение
RU2329263C2 (ru)	2008-07-20	Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с
RU2003115429A (ru)	2004-12-10	Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с
PT100620A (pt)	1993-09-30	Derivados de tetra-hidrocarbazol, seu uso e preparacao e composicoes farmaceuticas que os contem
HUP0203971A2 (hu)	2003-03-28	Imidazoimidazolok és -triazolok mint gyulladásellenes szerek és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AR039127A1 (es)	2005-02-09	Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
ATE448226T1 (de)	2009-11-15	Aza heterocyclische derivate und ihre therapeutische verwendung
RU93058534A (ru)	1997-02-10	Применение производных тетрагидрокарбазола в качестве антагонистов 5-нт*001 рецептора, производные тетрагидрокарбазола, способ их получения, способ лечения и фармацевтическая композиция
EA200300718A1 (ru)	2003-10-30	Производные 3-индолина, которые могут применяться при лечении психиатрических и неврологических расстройств
MXPA01004256A (es)	2003-06-06	N-arilamidas del acido antranilico y del acido tioantranilico.
TR200100300T2 (tr)	2001-07-23	Sitokinlerin üretiminde engelleyici olarak kullanışlı amid türevleri
ATE204873T1 (de)	2001-09-15	Naphthyridinderivate als angiotensin-ii- antagonist-inhibitoren
NO882036D0 (no)	1988-05-10	Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske ketoner.
ATE163012T1 (de)	1998-02-15	N-substituierte 4-pyrimidinamine und - pyrimidindiamine, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel
DZ1694A1 (fr)	2002-02-17	"n-(2-Aminoethyl)-benzothialozones".
BG98216A (en)	1994-08-15	Benzofuran derivatives
CA2431952A1 (en)	2002-07-04	Muscarinic antagonists
SE0101579D0 (sv)	2001-05-04	New compounds
RU2001135802A (ru)	2003-08-27	Антагонисты рецептора брадикинина
EP0309422A3 (en)	1990-01-10	New amidino tricycle derivatives
ATE201671T1 (de)	2001-06-15	Chinolon und acridinon derivate zur behandlung der harninkontinenz
EA200200650A1 (ru)	2002-12-26	Замещенные производные пиперазина в качестве ингибиторов мтр-протеина
AU2011271480B2 (en)	2014-09-11	Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity
CY1115353T1 (el)	2017-01-04	Νεα παραγωγα υποκατεστημενης τετρακυκλικης ιμιδαζολης, διαδικασιες για την παρασκευη τους, φαρμακευτικες συνθεσεις που τα περιλαμβανουν και η χρηση τους ως φαρμακο

Legal Events

Date	Code	Title	Description
2005-06-27	FA92	Acknowledgement of application withdrawn (lack of supplementary materials submitted)	Effective date: 20050513